Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer

Figures & data

Table 1. The primary characteristics of 98 patients with mCRC.

Variable	number	Percentage(%)
Age(year)
≤60	62	63.27
>60	36	36.73
Gender
Male	51	52.04
Female	47	47.96
Tumor site
Colon	49	50.00
Rectum	49	50.00
Tumor Grade
High-Middle	65	66.37
Low	33	33.63
Metastatic Site
Liver	60	61.22
Other	38	38.78

Figure 1. Immunohistochemistry of TOPO-1 in CRC tissues. (A) High expression of TOOPO-1. (B) Low expression of TOPO1. Scale bar = 100 µm.

Figure 2. Immunohistochemistry of CES-2 in CRC tissues. (A) High expression of CES-2. (B) Low expression of CES-2. Scale bar = 100 µm.

Table 2. The correlation of TOPO-1 and CES-2 expression in patients.

TOPO-1	CES-2	N	P value
high	high	29	0.094
high	low	17
low	high	24
low	low	28

Table 3. The correlation between TOPO-1 expression and clinicopathological characteristics in mCRC patients.

Clinicopathological characteristics	N	high expression (n = 46) (%)	low expression (n = 52) (%)	P value
Age(year)
≤60	62	28(45.16)	34(54.94)	0.463
>60	36	18(50.00)	18(50.00)
Gender
Male	51	21(41.18)	30(58.82)	0.234
Female	47	25(53.19)	22(46.81)
Tumor site
Colon	49	19(38.78)	30(61.22)	0.105
Rectum	49	27(55.10)	22(44.90)
Tumor grade
High-Middle	65	30(46.15)	35(53.85)	0.827
Low	33	16(48.48)	17(51.52)
Metastatic Site
Liver	60	26(43.33)	34(56.67)	0.899
Other	38	20(52.63)	18(47.37)

Table 4. The correlation between CES-2 expression and clinicopathological characteristics in mCRC patients.

Clinicopathologicalcharacteristics	N	High expression (n = 53) (%)	Low expression (n = 45) (%)	P value
Age(year)
≤60	62	33(53.23)	29(46.77)	0.933
>60	36	20(55.56)	16(44.44)
Gender
Male	51	26(50.98)	25(49.02)	0.521
Female	47	27(57.45)	20(42.55)
Tumor site
Colon	49	28(47.46)	21(42.86)	0.543
Rectum	49	25(51.02)	24(48.98)
Tumor grade
High-Middle	65	35(53.85)	30(46.15)	0.948
Low	33	18(54.55)	15(45.45)
Metastatic Site
Liver	60	34(56.67)	26(42.11)	0.369
Other	38	18(47.37)	20(52.63)

Table 5. The correlation of TOPO-1 and CES-2 expression in mCRC with curative effect.

Tumor marker	N	RR(CR+PR) N (%)	P value
TOPO-1
high	46	23 (50.00)	0.052
low	52	16 (30.77)
CES-2
high	53	26 (49.06)	0.042
low	45	13 (28.89)

Table 6. Compare the expression of TOPO-1, CES-2 in mCRC and the curative effect.

TOPO-1	CES-2	N	RR(CR+PR) N (%)	P value
high	high	29	18 (62.07, 95% CI: 42.3–79.3)	0.009
high	low	17	7 (41.18, 95% CI:18.4–67.1)
low	high	24	9 (37.50, 95% CI: 18.8–59.4)
low	low	28	5 (17.86, 95% CI: 6.1–36.9)

Figure 3. ROC curves analysis of TOPO-1 and CES-2 expression in the CRC tissues. (A) ROC curve for TOPO-1 discriminates the curative effect. (B) ROC curve for CES-2 discriminates the curative effect.

Figure 4. The relationship between TOPO-1 expression/CES-2 expression and the PFS in patients with mCRC. (A) Kaplan-Meier curves for PFS in mCRC patients correlation with TOPO-1 expression in CRC tissues (P = 0.00101). (B) Kaplan-Meier curves for PFS in mCRC patients correlation with CES-2 expression in CRC tissues (P = 0.046).

Figure 5. The relationship between TOPO-1 expression/CES-2 expression and the OS in patients with mCRC. (A) Kaplan-Meier curves for OS in mCRC patients correlation with TOPO-1 expression in CRC tissues (P = 0.00273). (B) Kaplan-Meier curves for OS in mCRC patients correlation with CES-2 expression in CRC tissues (P = 0.0077).